US EditionPublished • loading... • Updated
UK's GSK Announces $30 Billion U.S. Pharma Investment Amid Trump State Visit
GSK will allocate $1.2 billion to build a biologics factory in Pennsylvania and upgrade digital technologies at five U.S. sites, enhancing drug discovery and manufacturing capacities.
- GSK announced on 16 September 2025 a $30 billion investment in US research and manufacturing over the next five years during President Trump's UK state visit.
- This announcement came after AstraZeneca and Merck scaled back their UK investments, highlighting difficulties such as unfavorable pharmaceutical pricing policies and challenges related to funding research and development.
- GSK's investment includes $1.2 billion for new biologics factories in Pennsylvania and AI-enhanced technologies across five US manufacturing sites in multiple states.
- CEO Emma Walmsley highlighted that the state visit celebrates the partnership between two nations recognized for their leadership in scientific and healthcare advancements, reaffirming GSK’s ongoing commitment to the UK.
- Prime Minister Keir Starmer described the US investment as a “powerful example” of UK-US collaboration likely to create jobs and boost pharmaceutical innovation on both sides.
Insights by Ground AI
20 Articles
20 Articles
The British pharmaceutical laboratory GSK announced on Wednesday 17 September an investment of $30 billion (about 25 billion euros) over five years in the United States, on the first day of Donald Trump's state visit to the United Kingdom.
Coverage Details
Total News Sources20
Leaning Left2Leaning Right3Center6Last UpdatedBias Distribution55% Center
Bias Distribution
- 55% of the sources are Center
55% Center
L 18%
C 55%
R 27%
Factuality
To view factuality data please Upgrade to Premium
